Literature DB >> 28606965

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.

Elke Ea Arts1, Jaap Fransen2, Alfons A Den Broeder3, Piet L C M van Riel4,5, Calin D Popa1,3.   

Abstract

OBJECTIVE: Systemic inflammation appears to contribute to the excess risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The objective of this study was to investigate the effect of different levels of disease activity over time, particularly low disease activity and remission, on CVD risk in patients with RA.
METHODS: Data from the Nijmegen early RA inception cohort were used. The primary outcome was first CVD events within the first 10 years of follow-up. Cut points of the DAS28 for remission (<2.6) and low (≤3.2), moderate (3.2-5.1) and high (>5.1) disease activity were used. The effect of disease activity on CVD risk was analysed using Cox-proportional hazards regression with DAS28 as a time-dependent covariate and also conventionally with time-averaged DAS28 as the primary dependent variable.
RESULTS: Low DAS28 (≤3.2) was significantly associated with a reduced risk of CVD (HR 0.65, 95% CI 0.43 to 0.99) compared with DAS28 >3.2, both when included as a time-dependent covariate and as time-averaged DAS28 ≤3.2 (HR 0.52, 95% CI 0.33 to 0.81). Remission had a modest, non-significant protective effect against CVD (HR 0.67, 95% CI 0.43 to 1.07).
CONCLUSION: Results of this study suggest that low disease activity is sufficient to achieve a protective effect against CVD in RA. Apparently, remission defined as DAS28 <2.6 has no additional protective effect against CVD compared with low disease activity. Our results strengthen the use of tight control strategies in daily clinical practice to achieve low stable disease activity or remission in patients with RA as soon as possible. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Cardiovascular Disease; Disease Activity; Rheumatoid Arthritis

Mesh:

Year:  2017        PMID: 28606965     DOI: 10.1136/annrheumdis-2016-210997

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Diastolic dysfunction in rheumatoid arthritis patients with low disease activity.

Authors:  Bożena Targońska-Stępniak; Małgorzata Biskup; Wojciech Biskup; Maria Majdan
Journal:  Clin Rheumatol       Date:  2018-12-12       Impact factor: 2.980

2.  Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis.

Authors:  Zhi Yu; Nicole Yang; Brendan M Everett; Michelle Frits; Christine Iannaccone; Jonathan Coblyn; Michael Weinblatt; Nancy Shadick; Daniel H Solomon; Katherine P Liao
Journal:  Arthritis Rheumatol       Date:  2018-08-01       Impact factor: 10.995

Review 3.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

4.  Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.

Authors:  John M Davis; Jaeyun Sung; Benjamin Hur; Vinod K Gupta; Harvey Huang; Kerry A Wright; Kenneth J Warrington; Veena Taneja
Journal:  Arthritis Res Ther       Date:  2021-06-08       Impact factor: 5.156

5.  Improved Incidence of Cardiovascular Disease in Patients With Incident Rheumatoid Arthritis in the 2000s: A Population-based Cohort Study.

Authors:  Elena Myasoedova; John M Davis; Veronique L Roger; Sara J Achenbach; Cynthia S Crowson
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

Review 6.  Mechanisms of vascular comorbidity in autoimmune diseases.

Authors:  György Nagy; Nóra Németh; Edit I Buzás
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

Review 7.  Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.

Authors:  Qiang Guo; Yuxiang Wang; Dan Xu; Johannes Nossent; Nathan J Pavlos; Jiake Xu
Journal:  Bone Res       Date:  2018-04-27       Impact factor: 13.567

Review 8.  Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?

Authors:  Przemyslaw J Kotyla
Journal:  Int J Mol Sci       Date:  2018-06-12       Impact factor: 5.923

9.  Incident arterial vascular events in a cohort of Puerto Ricans with rheumatoid arthritis.

Authors:  Ariana González-Meléndez; Ruth M Fred-Jiménez; Mariangelí Arroyo-Ávila; Leyda Díaz-Correa; Naydi Pérez-Ríos; Noelia Rodríguez; Grissel Ríos; Luis M Vilá
Journal:  SAGE Open Med       Date:  2020-09-15

10.  Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity.

Authors:  Małgorzata Biskup; Wojciech Biskup; Maria Majdan; Bożena Targońska-Stępniak
Journal:  Rheumatol Int       Date:  2018-05-17       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.